

Rec'd PCT/PTC 02 DEC 2004  
T4/03/457 #2

REC'D 30 OCT 2003  
WIPO PCT

PA 1072922

**THE UNITED STATES OF AMERICA**

**TO ALL TO WHOM THESE PRESENTS SHALL COME:**

**UNITED STATES DEPARTMENT OF COMMERCE**

**United States Patent and Trademark Office**

**October 03, 2003**

**THIS IS TO CERTIFY THAT ANNEXED HERETO IS A TRUE COPY FROM  
THE RECORDS OF THE UNITED STATES PATENT AND TRADEMARK  
OFFICE OF THOSE PAPERS OF THE BELOW IDENTIFIED PATENT  
APPLICATION THAT MET THE REQUIREMENTS TO BE GRANTED A  
FILING DATE UNDER 35 USC 111.**

**APPLICATION NUMBER: 60/393,747**

**FILING DATE: July 08, 2002**

**PRIORITY  
DOCUMENT**

SUBMITTED OR TRANSMITTED IN  
COMPLIANCE WITH RULE 17.1(a) OR (b)

**By Authority of the  
COMMISSIONER OF PATENTS AND TRADEMARKS**



  
**M. K. HAWKINS**

**Certifying Officer**

1031 U.S. PTO  
07/08/02

Please type a plus sign (+) inside this box

602937-47-U70R0P

*At prov*

PTO/SB/16 (8-00)  
Approved for use through 10/31/2002 OMB 0651-0032

U S Patent and Trademark Office, U S. DEPARTMENT OF COMMERCE  
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

## PROVISIONAL APPLICATION FOR PATENT COVER SHEET

This is a request for filing a PROVISIONAL APPLICATION FOR PATENT under 37 CFR 1.53(c).

| INVENTOR(S)  |   |  |                    |     |                        |
|--|---|--|--------------------|-----|------------------------|
| Given Name (first and middle if any)   | Family Name or Surname                  | Residence<br>(City and either State or Foreign Country)                        |                    |     |                        |
| YOSSEF<br>ORY<br>AMOTZ<br>DAVID  | KLIGER<br>ZIK<br>NECHUSHTAN<br>SPRINZAK | RISHON LE'ZION, ISRAEL<br>REHOVOT, ISRAEL<br>ASERET, ISRAEL<br>REHOVOT, ISRAEL |                    |     |                        |
| <input type="checkbox"/> Additional inventors are being named on the _____ separately numbered sheets attached hereto                                |   |  |                    |     |                        |
| <b>TITLE OF THE INVENTION (280 characters max)</b>   |   |  |                    |     |                        |
| QUANTITATIVE PATTERN ANALYSIS OF MOLECULES ON INTACT CELLS USING AUTOMATED SEM   |   |  |                    |     |                        |
| Direct all correspondence to:  |   |  |                    |     |                        |
| CORRESPONDENCE ADDRESS   |   |  |                    |     |                        |
| <input checked="" type="checkbox"/> Customer Number  | 24505                                   | <input type="button" value="→"/>   |                    |     |                        |
| OR   | Type Customer Number here               |  |                    |     |                        |
| Firm or Individual Name  | DANIEL J. SWIRSKY                       |  |                    |     |                        |
| Address  | ALPHAPATENT ASSOCIATES LTD.             |  |                    |     |                        |
| Address  | P.O.B. 2345                             |  |                    |     |                        |
| City   | BEIT SHEMESH                            | State  | ISRAEL             | ZIP | 99544                  |
| Country  | ISRAEL                                  | Telephone  | 011-972-2-999-1035 | Fax | 011-972-2-999-7638     |
| <b>ENCLOSED APPLICATION PARTS (check all that apply)</b>   |   |  |                    |     |                        |
| <input checked="" type="checkbox"/> Specification Number of Pages  | 29                                      | <input type="checkbox"/> CD(s), Number   |                    |     |                        |
| <input checked="" type="checkbox"/> Drawing(s) Number of Sheets  | 8                                       | <input type="checkbox"/> Other (specify)                                       |                    |     |                        |
| <input type="checkbox"/> Application Data Sheet. See 37 CFR 1.76   |   |  |                    |     |                        |
| <b>METHOD OF PAYMENT OF FILING FEES FOR THIS PROVISIONAL APPLICATION FOR PATENT</b>  |   |  |                    |     |                        |
| <input checked="" type="checkbox"/> Applicant claims small entity status. See 37 CFR 1.27.   |   |  |                    |     | FILING FEE AMOUNT (\$) |
| <input type="checkbox"/> A check or money order is enclosed to cover the filing fees   |   |  |                    |     | \$80.00                |
| <input checked="" type="checkbox"/> The Commissioner is hereby authorized to charge filing fees or credit any overpayment to Deposit Account Number: | 501380                                  |  |                    |     |                        |
| <input type="checkbox"/> Payment by credit card. Form PTO-2038 is attached.  |   |  |                    |     |                        |
| The invention was made by an agency of the United States Government or under a contract with an agency of the United States Government.              |   |  |                    |     |                        |
| <input checked="" type="checkbox"/> No   |   |  |                    |     |                        |
| <input type="checkbox"/> Yes, the name of the U.S. Government agency and the Government contract number are. _____                                   |   |  |                    |     |                        |

Respectfully submitted,

Date 7/8/02

SIGNATURE

TYPED or PRINTED NAME DANIEL J. SWIRSKY

TELEPHONE 011-972-2-999-1035

REGISTRATION NO.  
(if appropriate)  
Docket Number.

45,148

1143-USP

## USE ONLY FOR FILING A PROVISIONAL APPLICATION FOR PATENT

This collection of information is required by 37 CFR 1.51. The information is used by the public to file (and by the PTO to process) a provisional application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 8 hours to complete, including gathering, preparing, and submitting the complete provisional application to the PTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, Washington, D.C. 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Box Provisional Application, Assistant Commissioner for Patents, Washington, D.C. 20231.

1031 U.S. PTO  
07/08/02

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

# FEE TRANSMITTAL for FY 2002

Patent fees are subject to annual revision

TOTAL AMOUNT OF PAYMENT (\$ 80.00)

## Complete if Known

|                      |                |
|----------------------|----------------|
| Application Number   |                |
| Filing Date          | JULY 8, 2002   |
| First Named Inventor | KLIGER, YOSSEF |
| Examiner Name        |                |
| Group Art Unit       |                |
| Attorney Docket No.  | 1143-USP       |

## METHOD OF PAYMENT

1.  The Commissioner is hereby authorized to charge indicated fees and credit any overpayments to  
 Deposit Account Number **501380**  
 Deposit Account Name **ALPHAPATENT ASSOCIATES LTD.**
- Charge Any Additional Fee Required Under 37 CFR 1.16 and 1.17  
 Applicant claims small entity status See 37 CFR 1.27
2.  Payment Enclosed.  
 Check  Credit card  Money Order  Other

## FEE CALCULATION

## 1. BASIC FILING FEE

| Large Entity       | Small Entity           | Fee Code (\$) | Fee Code (\$) | Fee Description | Fee Paid |
|--------------------|------------------------|---------------|---------------|-----------------|----------|
| 101 740 201 370    | Utility filing fee     |               |               |                 |          |
| 106 330 208 165    | Design filing fee      |               |               |                 |          |
| 107 510 207 255    | Plant filing fee       |               |               |                 |          |
| 108 740 208 370    | Reissue filing fee     |               |               |                 |          |
| 114 160 214 80     | Provisional filing fee |               |               |                 |          |
| <b>SUBTOTAL(I)</b> | <b>(\$ 80.00)</b>      |               |               |                 |          |

## 2. EXTRA CLAIM FEES

| Total Claims       | -20- =  | Extra Claims | Fee from below | Fee Paid |
|--------------------|---------|--------------|----------------|----------|
| Independent Claims | - 3 - = |              | X              |          |
| Multiple Dependent |         |              |                |          |

| Large Entity        | Small Entity | Fee Code (\$) | Fee Description  |
|---------------------|--------------|---------------|--|
| 103 18 203 9        |              |               | Claims in excess of 20                                     |
| 102 84 202 42       |              |               | Independent claims in excess of 3                          |
| 104 280 204140      |              |               | Multiple dependent claim, if not paid                      |
| 109 84 209 42       |              |               | ** Reissue independent claims over original patent         |
| 110 18 210 9        |              |               | ** Reissue claims in excess of 20 and over original patent |
| <b>SUBTOTAL (2)</b> | <b>(\$)</b>  |               |  |


\*\*or number previously paid, if greater. For Reissues, see above

## FEE CALCULATION (continued)

## 3. ADDITIONAL FEES

| Large Entity          | Small Entity | Fee Code (\$) | Fee Description  | Fee Paid |
|-----------------------|--------------|---------------|--|----------|
| 105 130 205 65        |              |               | Surcharge - late filing fee or oath  |          |
| 127 50 227 25         |              |               | Surcharge - late provisional filing fee or cover sheet                     |          |
| 139 130 139 130       |              |               | Non-English specification  |          |
| 147 2,520 147 2,520   |              |               | For filing a request for ex parte reexamination                            |          |
| 112 920* 112 920*     |              |               | Requesting publication of SIR prior to Examiner action                     |          |
| 113 1,840* 113 1,840* |              |               | Requesting publication of SIR after Examiner action                        |          |
| 115 110 215 55        |              |               | Extension for reply within first month                                     |          |
| 116 400 216 200       |              |               | Extension for reply within second month                                    |          |
| 117 920 217 480       |              |               | Extension for reply within third month                                     |          |
| 118 1,440 218 720     |              |               | Extension for reply within fourth month                                    |          |
| 128 1,960 228 980     |              |               | Extension for reply within fifth month                                     |          |
| 119 320 219 160       |              |               | Notice of Appeal   |          |
| 120 320 220 180       |              |               | Filing a brief in support of an appeal                                     |          |
| 121 280 221 140       |              |               | Request for oral hearing   |          |
| 138 1,510 138 1,510   |              |               | Petition to Institute a public use proceeding                              |          |
| 140 110 240 55        |              |               | Petition to revive - unavoidable   |          |
| 141 1,280 241 640     |              |               | Petition to revive - unintentional   |          |
| 142 1,280 242 640     |              |               | Utility issue fee (or reissue)   |          |
| 143 460 243 230       |              |               | Design issue fee   |          |
| 144 620 244 310       |              |               | Plant issue fee  |          |
| 122 130 122 130       |              |               | Petitions to the Commissioner  |          |
| 123 50 123 50         |              |               | Processing fee under 37 CFR 1.17(q)  |          |
| 126 180 126 180       |              |               | Submission of Information Disclosure Stmt                                  |          |
| 581 40 581 40         |              |               | Recording each patent assignment per property (times number of properties) |          |
| 146 740 246 370       |              |               | Filing a submission after final rejection (37 CFR § 1.129(e))              |          |
| 149 740 249 370       |              |               | For each additional invention to be examined (37 CFR § 1.129(b))           |          |
| 178 740 279 370       |              |               | Request for Continued Examination (RCE)                                    |          |
| 169 900 169 900       |              |               | Request for expedited examination of a design application                  |          |
| Other fee (specify)   |              |               |  |          |

\*Reduced by Basic Filing Fee Paid SUBTOTAL (3) (\$)

|                   |   |                                  |                    |
|-------------------|---|----------------------------------|--------------------|
| SUBMITTED BY      |   | Complete (if applicable)         |                    |
| Name (Print/Type) | DANIEL J. SWIRSKY   | Registration No (Attorney/Agent) | 45,148             |
| Signature         |  | Telephone                        | 011-972-2-999-1035 |
| Date              | JULY 8, 2002  |                                  |                    |

WARNING: Information on this form may become public. Credit card information should not be included on this form. Provide credit card information and authorization on PTO-2038.

Burden Hour Statement This form is estimated to take 0 2 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO Assistant Commissioner for Patents, Washington, DC 20231

**Provisional Patent Application**

**Title: Quantitative Pattern Analysis of Molecules On Intact Cells Using  
Automated SEM**

5

**Inventors:**

Yossef Kliger, an Israeli citizen, of Rishon Le'Zion.

Ory Zik, an Israeli citizen, of Rehovot.

Amotz Nechushtan, an Israeli citizen, of Aseret.

10 David Sprinzak, an Israeli citizen, of Rehovot.

**FIELD OF THE INVENTION**

The present invention discloses a device and methods for analyzing the pattern and the spatial distribution of biological molecules in intact cells at cellular and 15 subcellular levels, with the resolution of electron microscopy combined with the throughput and ease of sample preparation of light microscopy. The invention specifically enables analyzing the distribution of proteins on the cell surface by means of scanning electron microscopy, more particularly providing means enabling automated scanning electron microscopy using gold as well as fluorescence labeling, 20 wherein the samples may be dry or wet, live or fixed.

**BACKGROUND OF THE INVENTION**

The complex array of structure-function relationships in biochemical processes put an ongoing challenge to researchers in the area. One major limitation in such 25 studies is the difficulty in tracking biochemical processes, qualitatively and quantitatively, within the cellular context. A specific subgroup of proteins where such an analysis can be of merit is cell-surface receptors, as this class of proteins

constitutes more than fifty percent of the currently known drug targets.

Information such as protein translocation, distribution of membrane proteins and distribution of proteins in relation to specific organelles, is important for the understanding of cellular processes as well as for examining drug action.

- 5 One specific example of such processes are the signaling pathways, which involve receptor-ligand interactions, wherein a change in the receptor configuration or in its spatial distribution on the cell surface reflects a change in the cell status. Elucidating receptor - ligand interactions may enlighten many processes, including pathological developments leading to a disease, and may therefore also have a crucial 10 diagnostic value. However, most existing techniques used in this research area are indirect, measuring the result coming of the receptor change and not the change itself. In particular, changes in the spatial distribution of receptors such as homo and hetero dimerization are not currently assayed.

- Cell examination by various electron microscopic techniques would have served 15 as an excellent tool for the direct measurements of living cells; yet, existing techniques still lack fundamental capabilities for analyses of live or fixed wet samples. This long-needed analysis can be achieved by combining the properties of high resolution, high signal to noise ratio, the option to inspect wet samples, automation (which requires low input sample preparation and enables screening of 20 many samples) and the ability to measure dry or wet samples without the need of careful drying and coating.

- One additional limitation of presently available techniques is the tagging system: fluorescent tagging, typically scanned with a laser scanner, tends to undergo bleaching after one scanning, meaning that the fluorescent tags emit light that is 25 below the required intensity for detection, lowering the sensitivity and suffering also

from poor signal to noise ratio and resolution. Tagging methods that enable the use of scanning electron microscopy acquire the limitations of the EM devices, including a small scanned area that, in the absence of automation, and limits the ability to have statistical analysis required in studying such events.

5       The present invention relates to a novel technology utilizing known principles of automatic SEM from different industries, such as the semi-conductor industry, in which Wafer-Inspection Scanning Electron Microscopy (WISEM), disclosed in US Patents 6072178, 5644132, 5502306, 4618938 and 4609809, the contents of which are incorporated herein by reference, are widely used for quality control during the  
10 manufacturing process. The use of WISEM and ESEM was previously disclosed by one of the present inventors (WO 02/14830) to inspect fixed arrays of isolated biological molecules outside their natural environment, e.g. the cell. The present invention uses these principles for analyzing the pattern and the spatial distribution of biological molecules in intact cells at cellular and subcellular levels.

15      The ability to scan wet samples was disclosed in co-pending International Application (WO 02/45125) by one of the present inventors, the content of both applications being incorporated herein in their entirety.

However, the ability to obtain information regarding molecular pathways and inter-molecular interactions within the context of intact cells was not taught by any of  
20 these disclosures.

Thus, there is a great need for, and it would be highly advantageous to have methods and devices that will enable automated measurements of biological molecules under natural, minimally disrupted or unperturbed environment.

## 25   SUMMARY OF THE INVENTION

It is an object of the present invention to provide methods and devices for

analyzing the pattern and the spatial distribution of biological molecules that are based on single-molecule detection, show high sensitivity and are capable of measuring the monomeric, dimeric or multimeric state of the molecule of interest. It is another object of the present invention to provide the means to enable such analyses

5      in an intact cell, in a dry as well as in a wet sample.

It is yet another object of the present invention to provide such methods for analyzing the pattern and the spatial distribution of biological molecules in an automated manner, enabling the requisite number of measurements for proper analyses.

10     The present invention describes technology that for the first time permits the use of automated SEM in cell biology, by combining existing automatic SEMs with liquid handling and robotics developed mainly for automated fluorescence microscopy. For this purpose the present invention describes an array of chambers comprising cavities in which the samples are grown, and the features required to allow the combination of

15    these arrays with existing SEM equipment. In addition, the present invention describes assays for patterning of molecules on a biological specimen. Therefore, the present invention allows, for the first time, automated cell-based assays using SEM, capable of discerning molecular interactions at resolutions previously unattainable.

In one aspect the present invention provides a method for analyzing the pattern  
20    and spatial distribution of at least a first detectable member relative to a second detectable member in a biological specimen, the biological specimen comprising intact cells, comprising the steps of labeling at least one detectable member; loading the specimen into the specimen chamber of a scanning electron microscope; irradiating the specimen with an electron beam, observing at least one of secondary,  
25    backscattered electrons and photons emerging from said chamber, thus obtaining an

image representing at least one member of the specimen; and analyzing the image for the spatial distribution of said members by image analysis software.

In one embodiment the members are biological molecules, wherein said biological molecules may be identical, capable of changing cellular spatial  
5 distribution according to specific physiological condition either stimulated or not.

In one embodiment the first and the second detectable members are biological molecules, wherein said biological molecules may be identical, capable of creating homo-multimers, or different, capable of creating hetero-multimers.

In another embodiment, one of the detectable members is a biological structure,  
10 such as membrane domain or subcellular organelle.

In yet another embodiment, one of the detectable members is an exogenous protein like viral or bacterial.

In yet another embodiment one of the detectable members is a viral particle.

In a preferred embodiment, the biological molecules are labeled with a marker  
15 suitable for detection by SEM, exemplified by, but not restricted to scintillating beads or heavy atoms, such as gold, silver or iron.

In one preferred embodiment the diameter of the heavy metal colloids (e.g., gold), is at the range of 1-200 nm, more preferably less than 20 nm.

In yet another embodiment, multi-labeling is achieved, for example by using  
20 gold colloids of a plurality of sizes, or by using combination of gold colloids and fluorescent labels, or by using a plurality of metals that are read by the X-RAY reading apparatus of the SEM, such as by Energy Depressive Spectrum and the like.

According to one embodiment of the present invention the scanning electron microscope is a wafer inspection SEM (WISEM) typically used in the microelectronic  
25 industry. The irradiation of the specimen is carried out in such a way as to form

sufficient contrast of the electrons that are back scattered from the labeled molecules in comparison with those that are emitted/scattered from the background.

Surprisingly, the electrons that are back scattered from a non-labeled, non-coated cellular surface are intense enough to enable clear imaging of the cellular surface

- 5 without interfering with the image obtained for the labeled molecules.

In yet another embodiment the SEM system is an environmental scanning electron microscope (ESEM) that works at almost atmospheric pressure, thus minimizing the need to prepare the specimen for vacuum.

- In yet one preferred embodiment the SEM system is a system adapted for  
10 imaging of wet samples, as disclosed in co-pending International Application (WO 02/45125) by the present authors, the content of which is hereby incorporated in its entirety.

- In yet another currently preferred embodiment the SEM system is furnished with automation compatible chamber that enables electron microscopy of single and  
15 multiple samples.

- Any image analysis software that can automatically detect markers, such as gold colloids, may be appropriate. According to yet another aspect the image analysis of the present invention may comprise any one of: performing edge detection or image segmentation analysis algorithms to identify the colloids in each region-of-interest  
20 (ROI) and counting the colloids; counting fluorescence signals, identifying X-ray spectrum of each particle for identification by comparison to a reference spectrum, and algorithms for pattern distribution analysis, such as clustering algorithms.

- The present invention further relates to a device for inspection of a specimen of biological molecules, said biological molecules associated with or present in a  
25 specimen comprising intact cells, according to the above method. The device is a

- scanning electron microscope (SEM) comprising an electron source to provide an electron beam; a charged particle beam column to deliver and scan an electron beam from the electron source on the surface of the specimen; a vacuum system including a first and a second chamber in each of which pressurization can be performed
- 5 independently to permit loading or unloading of a first specimen in one chamber while simultaneously inspecting a second specimen; at least one electron detector; and/or fluorescence detector; means for measuring X-ray spectrum; a continuously moving x-y stage disposed to receive the specimen and to provide at least one degree of motion to the specimen while the specimen is being scanned by the electron beam;
- 10 and means for carrying out image analysis of the spatial patterning of the biological molecules of the specimen.

In one preferred embodiment, the charged particle beam column is a microcolumn.

- In yet another preferred embodiment, the device for inspection of a specimen of
- 15 biological molecules is a wafer inspection scanning electron microscope (WISEM), adapted for biological specimens similar to the devise described in the co-pending International Application WO 02/14830, the content of which is herein incorporated by its entirety.

- In yet further preferred embodiment, the device for inspection of a specimen of
- 20 biological molecules is an environmental scanning electron microscope (ESEM) that works at almost atmospheric pressure, thus minimizing the need to prepare the specimen for vacuum.

- In yet one another preferred embodiment the ESEM system is a system adapted for imaging of wet samples, as disclosed in co-pending International Application (WO
- 25 02/45125) by one of the present inventors, the content of which is hereby incorporated

in its entirety.

In yet another currently preferred embodiment the ESEM system is furnished with automation compatible chamber that enables electron microscopy of single and multiple samples.

5        In yet another aspect, the present invention provides a method for the inspection of biological molecules on a specimen using an electron beam, the method comprising localizing the biological molecules in space and labeling them with markers; pre-aligning specimen and read specimen number; reading a recipe that contains the information to be detected; loading the specimen on X-Y-T stage (T means tilt) of an  
10      electron beam device; aligning the specimen; moving XYT stage to analysis position; positioning the electron beam on the substrate accurately by measuring the position of the substrate; scanning the specimen at low resolution to create a specimen map, while enhancing contrast; determining the regions-of-interest (ROI) spots on the map that should be scanned in a high resolution; scanning the ROIs with the electron beam  
15      as the substrate is continuously moving with at least one degree of motion in an x-y plane; detecting electrons emanating from the substrate as a result of previous step and forming an image; enhancing the image contrast; storing both modified and bare image; analyzing the ROIs; and displaying the results.

In one embodiment, the specimen analyzed by such method is a wet sample.

20      In yet another embodiment, the specimen analyzed by such method is a dry sample, wherein the method further comprising the step of preparing the specimen for vacuum.

The specimens are prepared for vacuum by known standard methods that include drying to the required degree, protection with a membrane and freezing to  
25      prevent out-gassing. The preparation may also include fixation and coating with a

conductive layer to prevent charge accumulation; the routine of the present invention excludes this step.

The present invention successfully addresses the unmeet need for identifying and tracking complex biochemical processes with minimal interference of the cell  
5 natural states.

The present invention is explained in greater details in the description, Figures and claims below.

#### BRIEF DESCRIPTION OF THE DRAWINGS

10 FIG 1 Describes an automated system for the evaluation of the spatial distribution of biological molecules, specifically receptors on the surface of cells.

FIG 2 shows a detailed description of a cell containing cassette (20) according to one embodiment of the present invention.

FIG. 3 describes the membrane partition of the cassette.

15 FIG. 4 displays one embodiment of the current invention.

FIG. 5 shows immuno-gold labeling of HeLa cells using anti epidermal growth factor receptor (EGFR) monoclonal antibodies.

A. Control cells

20 B. Cells treated with epidermal growth factor (EGF) at 4°C, to induce oligomerization without internalization, prior to labeling.

FIG. 6A is a histogram of the distribution of the distances of each label to its nearest neighbor label, in HeLa cells immuno-gold labeled with anti-EGFR monoclonal antibodies after EGF application. The results are an average of 4 independent measurements. Solid line represents the theoretical random distribution of distances to nearest neighbors using the same average density of labels.

25 FIG. 6B is a histogram of the distribution of the distances of each label to its nearest

neighbor label in a random Monte Carlo simulation using the same density of labels and the same number of receptors. The results are an average of 4 independent simulations.

## 5 DESCRIPTION OF THE PREFERRED EMBODIMENTS

It is an object of the present invention to use scanning electron microscopy for analyzing the pattern and the spatial distribution molecules in intact cells.

It is another object of the present invention to integrate the known principles of wafer inspection scanning electron microscopy (WISEM) into the field of cell

10 biology.

It is a further object of the present invention to expand this integration by incorporating the technique of environmental scanning electron microscopy (ESEM).

It is yet another object of the present invention to include adaptations of the SEM or ESEM, such as the possibility to image a wet sample as disclosed by one of 15 the present inventors in the co-pending International Application WO 02/45125, and the use of automation compatible chamber as described herein below.

The present invention relates to methods and devices for analyzing the pattern and the spatial distribution of biological molecules, wherein the method and the device allows highest sensitivity of ultimately single molecule detection and yields 20 high signal to noise ratios, while at the same time retain simple sample preparation readily applicable for high throughput screening.

As used herein, the term biological molecule includes any molecule with biological relevance that may be associated with an intact cell, either intracellularly or extracellularly. This includes, but is not limited to: polysaccharides, small chemical 25 molecules such as lipids, peptides, hormones and other messengers, ATP GTP etc., drugs, non proteinaceous antigens and any homo- (e.g., protein-protein as example)

and hetero- (e.g., drug-protein, DNA-RNA, DNA-protein, etc.) complexes, as well as chemically modifications and derivatizations whether naturally occurring or man made, of all these different molecules.

In one aspect the present invention provides a method for analyzing the pattern  
5 and spatial distribution of at least a first detectable member relative to a second detectable member in a biological specimen comprising intact cells, comprising the steps of labeling at least one detectable member; loading the specimen into the specimen chamber of a scanning electron microscope; irradiating the specimen with an electron beam observing at least one of secondary electron, backscattered electrons  
10 and photons emerging from said chamber, thus obtaining an image representing at least one member of the specimen; and analyzing the image for the spatial distribution of said members by image analysis software.

In one embodiment the first and the second detectable members are biological molecules. The biological molecules can be identical or different, and are capable of  
15 creating multimers; identical molecules form homo-multimers while different molecules form hetero-multimers.

In another embodiment one of the detectable members is a biological structure, for example a cell organelle, or a domain in the plasma membrane.

The methods and devices disclosed in the present invention enable to determine  
20 whether a molecule is in the state of monomer or multimer. When the biological molecule is a receptor on the membrane cell, as exemplified herein below, this method provides the means for elucidating the relationships between the cell status and a specific receptor status, the information being highly valuable for understanding and diagnosing pathological conditions.

25 For example, many types of cancer are characterized by changes in the

abundance or activity of cell surface receptors, which often transmit external signals into the cell. Receptors for Epidermal Growth Factor (EGF) are involved in a wide variety of human cancers. Critical parameters in the activity of cell surface receptors are the amount of receptors displayed on the surface, the clustering of these molecules

5 to groups of dimers or other polymers (requirement for activation), and the removal of the receptors from the surface after activation. Another aspect is the prevalence of homo- and heterodimers of the different subtypes of the EGF receptor (known as erbB1 – erbB4), which cannot be addressed by standard radiometric or fluorescent assays. The high resolution and signal to noise ratio of the SEM and method disclosed

10 by the present invention make it uniquely suitable to measure these parameters. As such receptors are prime targets for anti-cancer drugs, the methods and devices disclosed in the present invention can serve as a powerful tool for drug discovery and drug screening.

Additional examples of receptors and other proteins that play a key role in

15 pathological disorders, thus amenable to be studied by the methods and devices of the present invention and benefit drug discovery are fibroblast growth factor receptors (FGFR) involved in growth of cartilage and bones; The glucose transporter 4 protein (GLUT4), one of the most relevant parameters of insulin activity; Cell surface molecules involved in the cell immune system, such as CD4 and CCR5 that HIV-1,

20 has to bind to in order to infect the cell; and different receptors responsible for the interaction of cells with disease-causing bacteria or viruses.

In a preferred embodiment, the biological molecules imaged by the methods and devices of the present invention are labeled directly or indirectly with a marker suitable for detection by SEM, exemplified by, but not restricted to scintillating beads

25 or heavy atoms. Preferably the biological molecules are indirectly tagged with a heavy

- atom. The heavy atom can be any atom capable of scattering particles better than the atoms that are present in all organic molecules, such as C, H, O, as well as N, S and P. Suitable heavy atoms include gold, silver and iron, which are frequently used in electron microscopy. Methods are known to link such heavy atoms to a variety of 5 organic molecules. For example, gold can covalently bind through an SH group which is natural to proteins and can be introduced in other molecules such as nucleic acids and polysaccharides. Other heavy atoms can be trapped in suitable chelators, which can be linked to a variety of macromolecules using methods well known in the art.
- 10 More preferably, the heavy atom is gold in colloids having a diameter in the range of 1-200 nm, most preferably having a diameter less than 20 nm. The colloidal gold creates a high intensity back scattered electron signal, and therefore, a high image contrast.
- In one embodiment, there is one label per target molecule.
- 15 In yet another embodiment, multi-labeling of more than one target molecule is achieved, for example by using gold colloids of a plurality of sizes, or by using combination of gold colloids and fluorescent labels, or by using a plurality of metals that are read by the X-ray reading apparatus of the SEM, such as by Energy Depressive Spectrum and the like.
- 20 According to one embodiment the scanning electron microscope used in the method of the present invention is a wafer inspection SEM (WISEM) typically used in the microelectronic industry. The irradiation of the specimen is carried out in such a way as to form sufficient contrast of the electrons that are back scattered from the labeled molecules in comparison with those that are emitted/scattered from the 25 background. Surprisingly, the electrons that are back scattered from a non-labeled,

non-coated cellular surface are intense enough to enable clear imaging of the cellular surface without interfering with the image obtained for the labeled molecules.

In yet another embodiment the SEM used in the method of the present invention is an environmental scanning electron microscope (ESEM) that works at almost 5 atmospheric pressure, thus minimizing the need to prepare the specimen for vacuum.

In yet one preferred embodiment the ESM or ESEM used in the method of the present invention is a system adapted for imaging of wet samples, as disclosed in co-pending International Application (WO 02/45125) by some of the present authors, the content of which is hereby incorporated in its entirety.

10 In yet another currently preferred embodiment the SEM or ESEM used in the method of the present invention is furnished with automation compatible chamber that enables electron microscopy of single and multiple samples, as described in Figs. 1-4.

An automated system for the evaluation of the spatial distribution of biological molecules, specifically receptors on the surface of cells, is depicted in Figure 1. A 15 scanning electron microscope (10) is fitted with automated stage and controls and dedicated image analysis software that control the movement of the stage. Said scanning electron microscope is fed with sample cassettes (20), through a vacuum load lock, from a cassette stack holder (30) in a vacuum compatible fashion (prior art). The cassette (20) is fed into the holder by a prior art robotic arm (40). Prior to 20 inspection in the SEM the samples are scanned with a prior art light microscope (50). The preliminary inspection enables the registration of cells coordinates and the identification of cells and regions of interest. The process is controlled by a computer (60), which also displays the results.

A detailed description of a cells cassette (20) according to one embodiment of 25 the present invention, is shown in Figure 2. The cells (21) are located inside an array

of cavities (22), detailed in Fig. 3 hereinbelow. The array of cavities is attached to a sealant spacer (23), typically made of silicon, which connects the array (22) to a well plate containing typically 96 wells, and means (25) to close and seal the cassette (20). The top surface of the cassette (28) is tightened to the bottom well plate (24) so that

5 all the cavities are aligned. An array of light guides (81), preferably made of plastic, is placed inside each of the wells in (24), so that when the sample is closed, the light guides are immersed on the cell medium. The light guides placed in the scanned well (84) transmit light (photons) (92) to another light guide (82), via an index matching, vacuum resistant oil (83). Said light guide (82) is connected to a photo-multiplier via a

10 vacuum feed-through. The electrons (91) that are back scattered from the sample are detected at the backscattered electron detector (94). A heating and temperature stabilization element is connected to the array (22), making use of the fact that the array of cavities is electrically conductive and therefore also a good conductor of heat.

The membrane partition of the cassette is shown in Figure 3. An electron

15 transparent membrane (26), protected by a grid (27) is attached to an array of cavities (29) by attachment means (25), said attachment means are one of silicon sealant shim, UV activated glue, epoxy glue or other. The array of cavities is detailed in Fig. 4 herein below. The array of cavities is attached to the multi-well plate via sealant attachment means (23).

20 One embodiment of the current invention is displayed in Figure 4. The data are obtained from backscattered electrons only in a dry or ESEM mode of a prior art Scanning Electron Microscope. In this embodiment, the cassette (29) is made from a flat surface preferably made of glass or silicon; the cells are situated inside flat cavities in the substrate. Said cavities are about 2mm deep. Samples should be

25 prepared for vacuum. This can be done in any appropriate way, such as critical point

drying, chemical drying, freeze drying, and air drying.

According to yet another aspect the image analysis of the present invention may comprise any one of: performing edge detection or image segmentation analysis algorithms to identify the colloids in each region-of-interest (ROI) and counting the 5 colloids; counting fluorescence signals; identifying X-ray spectrum of each particle for identification by comparison to a reference spectrum, and algorithms for pattern distribution analysis, such as clustering algorithms.

The present invention further relates to a device for inspection of a specimen of biological molecules according to the above method. The device is a scanning 10 electron microscope (SEM) comprising an electron source to provide an electron beam; a charged particle beam column to deliver and scan an electron beam from the electron source on the surface of the specimen; a vacuum system including a first and a second chamber in each of which pressurization can be performed independently to permit loading or unloading of a first specimen in one chamber while simultaneously 15 inspecting a second specimen; at least one electron detector; a fluorescence detector; means for measuring X-ray spectrum; a continuously moving x-y stage disposed to receive the specimen and to provide at least one degree of motion to the specimen while the specimen is being scanned by the electron beam; and means for carrying out image analysis of the molecules on the specimen.

20 In one preferred embodiment, the charged particle beam column is a microcolumn.

In yet another preferred embodiment, the device for inspection of a specimen of biological molecules according to the above method is a wafer inspection scanning 25 electron microscope (WISEM) adapted for biological specimens, similar to the device described in the co-pending International Application WO 02/14830, the contents of

which is herein incorporated by its entirety. According to specific features disclosed therein for use with isolated biological molecules, it is now disclosed that the patterning of EGFR, CCR5, and the co-clustering of CD4 and CCR5 can be measured.

- 5        In yet further preferred embodiment, the device for inspection of a specimen of biological molecules according to the above method is an environmental scanning electron microscope (ESEM) that works at almost atmospheric pressure, thus minimizing the need to prepare the specimen for vacuum.

In yet one another preferred embodiment the SEM or ESEM system is a system  
10      adapted for imaging of wet samples, as disclosed in co-pending International Application (WO 02/45125) by the present authors, the contents of which are hereby incorporated in their entirety. According to specific feature disclosed therein, it is now disclosed that the patterning of EGFR, CCR5, and the co-clustering of CD4 and CCR5 can be measured.

- 15        In yet another currently preferred embodiment the SEM or ESEM system is furnished with automation compatible chamber that enables electron microscopy of single and multiple samples.

In yet another aspect, the present invention provides a method for the inspection of biological molecules on a specimen using an electron beam, the method comprising  
20      localizing the biological molecules in space and labeling them with markers; pre-aligning specimen and read specimen number; reading a recipe that contains the information to be detected; loading the specimen on X-Y-T stage (T means tilt) of an electron beam device; aligning the specimen; moving XYT stage to analysis position; positioning the electron beam on the substrate accurately by measuring the position of  
25      the substrate; scanning the specimen at low resolution to create a specimen map,

while enhancing contrast; determining the regions-of-interest (ROI) spots on the map  
that should be scanned in a high resolution; scanning the ROIs with the electron beam  
as the substrate is continuously moving with at least one degree of motion in an x-y  
plane; detecting electrons emanating from the substrate as a result of previous step  
5 and forming an image; enhancing the image contrast; storing both modified and bare  
image; analyzing the ROIs; and displaying the results.

In one embodiment, the specimen analyzed by such method is a wet sample.

In yet another embodiment, the specimen analyzed by such method is a dry  
sample, wherein the method further comprising the step of preparing the specimen for  
10 vacuum.

The specimens are prepared for vacuum by known standard methods that  
include drying to the required degree, protection with a membrane and freezing to  
prevent out-gassing. The preparation may also include fixation and coating with a  
conductive layer to prevent charge accumulation; the routine of the present invention  
15 excludes this step.

The principles of the invention, of using SEM for analyzing the pattern and  
spatial distribution of molecules detectable in intact cell may be better understood  
with reference to the following non-limiting examples.

## 20 EXAMPLES

### Example 1: Determining the multimer state of EGFR by the method of the present invention

It is well accepted that the multimeric state of EGFR is a crucial step in the  
activation of this receptor. To determine the oligomerization events occurring during  
25 EGFR activation, HeLa cells were labeled using anti-EGFR monoclonal antibodies  
(mAB) following starvation and growth factor (EGF) induction. A second antibody

link to gold was attached to the anti-EGFR mAB. A control sample was treated the same except for the EGF induction. As shown in Fig. 5, higher fraction of clustered receptors is observed in cells treated with EGF (Fig. 5B) compared to the untreated cells (Fig. 5A). One way for analyzing the multimer state of the EGFR is by using the 5 matrix of the number of labeled members in a certain area. Typical results for the spatial distribution of the average number of gold particles found in 17.5 micro m<sup>2</sup> for the control HeLa cells and for the EGF-treated HeLa cells are shown in table 1 below:

**Table 1**

| Treatment | No. of Monomers | No. of Dimers | No. of Trimers | No. of Tetramers |
|-----------|-----------------|---------------|----------------|------------------|
| Control   | 44.5            | 7             | 3              | 0                |
| +EGF      | 49              | 15            | 4              | 1.33             |

10 \*Results are average of 4 independent experiments.

Moriki et al. (JMB (2001) 311,1011-1026), suggests that about 80% cell-surface EGFR are in pre-formed dimers. The current accepted model is that EGF induction, as specified here, leads to close to 100% of the EGFR to be in dimers or higher order multimers. Our results show increase of 20-30% in the fraction of multimeric vs. 15 monomeric state. Therefore, our results are consistent with what was known from the literature.

Another matrix that can be used for the same purpose is the distance distribution between each first labeled member and its nearest second labeled member.

Fig. 6 illustrates the use of this matrix for the same HeLa cell treated with EGF 20 described above. Fig. 6A and B analyze the same data with two different methods: Fig. 6A is a histogram of the distribution of the distances of each label to its nearest neighbor label; Fig. 6B is a histogram of the distribution of the distances of each label to its nearest neighbor label in a random Monte Carlo simulation using the same density of labels and the same number of receptors. Solid line represents the

theoretical random distribution of distances to nearest neighbors using the same average density of labels. The results are average of 4 independent simulations.

**Example 2: Mathematical model for estimating the absolute number of multimers from the observed distribution of labeled members.**

5       The process of labeling members of interest is not perfect, i.e. only a fraction of the members, receptors in this particular example, are labeled. This is due to the nature of the immunological labeling and our desire to keep to the minimum the non-specific labeling. Partial labeling is an experimental limitation, which can be dealt with using an appropriate mathematical model. As an example we show herein below  
 10      how we can estimate, in a simple case, the absolute number of multimers (of any order) from the observed distributions of labels imaged by the SEM. This estimation provides information on the actual distribution of receptors on the cell surface even though not all receptors are labeled.

15      The present mathematical model describes a simple situation, wherein only homo-multimers are considered.

Assume  $N$  receptors on a certain region of the cell surface. Out of these  $N$  receptors a fraction  $a_1$  is monomers (i.e.  $Na_1$  receptors are monomers). A fraction  $a_2$  is receptors which are part of dimers (i.e.  $Na_2$  receptors are part of dimers). A fraction  $a_3$  is receptors which are part of trimers (i.e.  $Na_3$  receptors are part of trimers), etc:

20      (1)                   $a_1 + a_2 + a_3 + \dots = 1$

Assume that the probability to label a receptor is  $f$  (i.e.  $Nf$  of the receptors are labeled) and that the probability of labeling one receptor does not depend on whether other receptors are labeled. This assumption is not necessarily correct in real life since it is likely that one gold colloid attached to a receptor, which is part of a multimer, can  
 25      interfere with the labeling of other receptors belonging to the same multimer.  
 Nevertheless, this assumption is adopted for simplicity.

The observed data can also be grouped to singlets, doublets, triplets etc. of labeled receptors. Assume that  $N_1$  gold colloids are in singlets,  $N_2$  gold colloids are in doublets,  $N_3$  gold colloids are in triplets, etc., are observed.

In the case where all receptors are labeled ( $f=1$ ), the real numbers equal to the measured numbers:  $N_1 = Na_1$ ,  $N_2 = Na_2$ ,  $N_3 = Na_3$ , etc.

To summarize:

The expected total number of labeled receptors,  $N_t$ , is:

$$(2) \quad N_t = Nf$$

For simplicity, we will consider first the case where trimer is the largest multimer existing in the sample. Generalization to higher multimers is straightforward.

$$(3) \quad N_t = Nf = (Na_1 + Na_2 + Na_3)f$$

The probability of observing  $N_1$  singlets (singly labeled sites) is the sum of the probability to label monomers and the probability to singly label dimers and the probability to singly label trimers. Therefore, the expected value of  $N_1$  is:

$$(4) \quad N_1 = Nf[a_1 + f(1-f)a_2 + f(1-f)^2a_3]$$

The factor  $f(1-f)a_2$  represents the probability to singly label a dimer and the factor  $f(1-f)^2a_3$  is the probability to singly label a trimer. In a similar manner, the expected value of  $N_2$  and  $N_3$  is given by:

$$20 \quad (5) \quad N_2 = Nf^2a_2 + f^2(1-f)a_3$$

$$(6) \quad N_3 = Nf^3a_3$$

From equations (3), (4), (5) and (6), and given the real total number of receptors,  $N$  (say from prior knowledge), we can estimate the real values of  $Na_1$ ,  $Na_2$ , and  $Na_3$ , from the observed  $N_1$ ,  $N_2$  and  $N_3$ ,

25 For convenience we denote:

$n_1 = N_1/N$ ,  $n_2 = N_2/N$ ,  $n_3 = N_3/N$ . The above equations are then rewritten (dividing by  $N$  on both sides of the equations (4), (5) and (6) and using eq. (3)) as:

$$(7) \quad f = N/N'$$

$$(8) \quad n_1 = a_1 + (1-f)a_2 + (1-f)^2a_3$$

$$5 \quad (9) \quad n_2 = fa_2 + f(1-f)a_3$$

$$(10) \quad n_3 = f^2a_3$$

So, the estimated fraction of the various multimers can be calculated by using:

$$(11) \quad a_3 = \frac{n_3}{f^2}$$

$$(12) \quad a_2 = \frac{n_2}{f} - (1-f)\frac{n_3}{f^2}$$

$$10 \quad (13) \quad a_1 = n_1 - (1-f)\frac{n_2}{f}$$

It is important to note that  $a_1$  does not depend on  $n_3$  directly but only through  $f$ .

This is a property that is generalized when higher order multimers are used. So in a general solution with multimers up to an order  $m$ :

$$(14) \quad a_i = \frac{n_i}{f^{i-1}} - (1-f)\frac{n_{i+1}}{f^i}$$

15 for  $i=1,2,3,\dots,m-1$  with  $m$  the highest order multimer, and

$$(15) \quad a_m = \frac{n_m}{f^{m-1}}$$

$f$  can be estimated by dividing the total number of observed labels (measured) by the total number of receptors (presumably known).

The value of  $a_1$  is specifically interesting since  $(1-a_1)$  is the fraction of receptors 20 which participate in multimers of any size.

Since  $f$  is the unknown factor in this calculation it is important to see whether

the observed data can provide information on it. This is achieved by the limit imposed on labeling efficiency,  $f$ , due to the observed ratio between number of doublets and number of singlets.

- In practice this is done by taking the limit of  $\alpha_1=0$ . i.e. all the receptors belong to 5 multimers. Given the observed  $n_1$  and  $n_2$ , the minimal value of  $f$  can be obtained by solving eq. (13) when  $\alpha_1=0$ :

$$(16) \quad 0 = n_1 - (1-f) \frac{n_2}{f}$$

The solution for Eq. 16 is:

$$(17) \quad f = \frac{n_2}{n_1 + n_2} = \frac{N_2}{N_1 + N_2}$$

- 10 This limit imposes a maximal value of the number receptors,  $N$ :

$$(18) \quad N = \frac{(N_1 + N_2)N_1}{N_2}$$

Eq. (13) can be rewritten in the form:

$$(19) \quad \alpha_1 = \text{const.} - \frac{n_2}{f} = \text{const.} - \frac{n_2}{N_1} N$$

- 15 The uncertainty on  $f$  and  $N$  (due to a lack of accurate a-priori knowledge) can be translated to an uncertainty on  $\alpha_1$ . Hence:

$$(20) \quad \Delta\alpha_1 = \left| \frac{n_2}{f^2} \right| \Delta f = \left| \frac{n_2}{N_1} \right| \Delta N$$

**Example 3: A functional cell-based assay for selecting compounds that inhibit the entry of HIV-1 into target cells**

- 20 A functional cell-based assay for selecting compounds that inhibit the entry of HIV-1 into its target cells is disclosed as an illustrative example. It is based on the knowledge that CCR5 and CD4 are the principal receptors used by HIV-1 for entry

into cells in primary infection. Affecting CCR5 expression, spatial distribution, and/or co-clustering with CD4 is believed to be a potent anti-HIV-1 treatment strategy.

- The prior art does not disclose any system with sufficient quality (in terms of resolution, throughput, biological relevance and so forth) to enable evaluation of drug candidates preventing the clustering of the viral receptors at the level of molecular interactions on the cell surface. Specifically, optical microscopes, resolution of which is limited by the wavelength of light, are practically limited to resolution in the sub micron range. In contrast, the high resolution of Electron Microscopy (EM) can reveal in-depth biological information (Singer II, et al. 2001. *J Virol* 75:3779-90). However, conventional EMs are too cumbersome, since manual systems cannot be used efficiently for drug discovery. So far, optical-fluorescence microscopy and Transmission Electron Microscopy (TEM) have been used as preferred technologies for CCR5 and CD4 studies. Fluorescence microscopy is limited by resolution and thus reveals unreliable results when trying to detect patterning of membrane proteins (Singer II, et al. 2001. *J Virol* 75:3779-90), and TEM is too cumbersome a tool to be employed for screening drug candidates. Gene transfection and over expression are required to overcome the low sensitivity of fluorescence-based techniques, and drastic procedures (e.g., freeze-fracturing or embedding and sectioning) during sample preparation for TEM may bias the results and limit the ability to survey many regions on the cell. Using electron microscopy in a cell-based assay, as described in the present invention, allows screening of drugs based on mechanism of action that was not used until now. The expected results are described below.

Good drug candidates will be defined as those that meet at least one of the following criteria:

- i. Decrease CCR5 expression level. The best candidates will totally eliminate CCR5

from the cell membrane. It is worth noting that as defined in the context of the present specification, "totally eliminating CCR5" means that the number of CCR5 on the cell membrane is too low to play any significant role. Optical methods, e.g. FACS, typically can detect 10,000 molecules or more on the cell surface. In these cases there

- 5 is a sufficient number of CCR5 molecules to enable the biological process. These molecules are not detected by optical means.

ii. Decrease the number of CCR5 in a microcluster

iii. Increase the distance between CCR5 molecules in a microcluster

Increase the distance between CCR5 microclusters and CD4 microclusters (According

- 10 to one possible theoretical mechanism HIV-1 requires that CD4 and CCR5 will be close to each other, since the same gp120/gp41 trimer must associate with both of them)

Good drug candidates will not:

1. Influence the number of cells. This can be monitored by evaluation of other  
15 essential molecules.
2. Influence the level of CD4 on the cell membrane. This can be monitored by evaluation of other essential molecules.
3. Influence any characteristics of CD4 spatial distribution (cluster formation, number  
of molecules in a cluster, distances between molecules in a cluster, distances between  
20 clusters). This can be monitored by evaluation of other essential molecules.

The foregoing description of the specific embodiments will so fully reveal the general nature of the invention that others can, by applying current knowledge, readily modify and/or adapt for various applications such specific embodiments without  
25 undue experimentation and without departing from the generic concept, and,

therefore, such adaptations and modifications should and are intended to be comprehended within the meaning and range of equivalents of the disclosed embodiments. It is to be understood that the phraseology or terminology employed herein is for the purpose of description and not of limitation. The means, materials,  
5 and steps for carrying out various disclosed chemical structures and functions may take a variety of alternative forms without departing from the invention. Thus the expressions "means to..." and "means for...", or any method step language, as may be found in the specification above and/or in the claims below, followed by a functional statement, are intended to define and cover whatever chemical structure, or whatever  
10 function, which may now or in the future exist which carries out the recited function, whether or not precisely equivalent to the embodiment or embodiments disclosed in the specification above, i.e., other means or steps for carrying out the same functions can be used; and it is intended that such expressions be given their broadest interpretation.

**CLAIMS**

1. A method for analyzing the pattern and spatial distribution of at least a first detectable member relative to a second detectable member in a biological specimen, the biological specimen comprising intact cells, comprising the steps of: labeling at least one detectable member; loading the specimen into the specimen chamber of a scanning electron microscope; irradiating the specimen with an electron beam; observing at least one of secondary and backscattered electrons emerging from said sample, thus obtaining an image representing at least one member of the specimen; and analyzing the image for the spatial distribution of said members by image analysis software.
- 5 2. The method of claim 1, wherein the first and the second detectable members are biological molecules.
- 10 3. The method of claim 2, wherein the biological molecules are identical
4. The method of claim 2, wherein the biological molecules are different, then  
15 the labels are different
5. The method of claim 1, wherein at least one of the detectable members is a biological structure.
6. The method of claim 1, wherein the biological molecules are labeled with a marker suitable for detection by SEM, selected from the group comprising of  
20 scintillating beads or heavy metals, fluorescent probes, fluorescent proteins, X-ray emitting probes
7. The method of claim 6, wherein the biological molecules are labeled with gold.
8. The method of claim 7, wherein the biological molecules are labeled with  
25 gold colloids with a diameter at the range of 1-200 nm.

9. The method of claim 8, wherein the biological molecules are labeled with gold colloids with a diameter of less than 20 nm.
10. The method of claim 6, wherein different biological molecules are labeled with different markers.  
5        11. The method of claim 1, wherein the scanning electron microscope is a wafer inspection scanning electron microscope (WISEM).
12. The method of claim 1, wherein the scanning electron microscope is an environmental scanning electron microscope (ESEM).  
10        13. The method of claim 1, wherein the scanning electron microscope is adapted for scanning wet samples.  
14. The method of claim 1, wherein the scanning electron microscope is furnished with automation compatible chamber enabling electron microscopy of single and multiple samples.  
15        15. The method of claim 1 wherein the image analysis is performed by a method selected from the group consisting of performing edge detection algorithm or image segmentation analysis to identify the colloids in each region of interest, counting fluorescence signals or identifying X-ray spectrum of the particles in comparison with a reference background.  
16. A scanning electron microscope comprising an electron source to provide an  
20        electron beam; an electron beam column to deliver and scan an electron beam from the electron source on the surface of a specimen, the specimen comprising intact cells in single or multiple cell chamber; a vacuum system including a first and a second chamber in each of which pressurization can be performed independently to permit loading or unloading of a first specimen in one chamber while simultaneously inspecting a second specimen; at least  
25

one electron detector; a continuously moving x-y stage disposed to receive the specimen and to provide at least one degree of motion to the specimen while the specimen is being scanned by the electron beam; and means for carrying out image analysis of spatial patterning of molecules of the specimen.

5

17. The scanning electron microscope of claim 16 adapted for use with wet samples.

10

18. A method for the inspection of biological molecules on a specimen, the specimen comprising intact cells, using an electron beam, the method comprising localizing the biological molecules in space and labeling them with markers; pre-aligning specimen and read specimen number; reading a recipe that contains the information to be detected; loading the specimen on X-Y-T stage (T means tilt) of an electron beam device; aligning the specimen; moving XYT stage to analysis position; positioning the electron beam on the substrate accurately by measuring the position of the substrate; scanning the specimen at low resolution to create a specimen map, while enhancing contrast; determining the regions-of-interest (ROI) spots on the map that should be scanned in a high resolution; scanning the ROIs with the electron beam as the substrate is continuously moving with at least one degree of motion in an x-y plane; detecting electrons emanating from the substrate as a result of previous step and forming an image; enhancing the image contrast; storing both modified and bare image; analyzing the ROIs; and displaying the results.

15

20




Figure 1




Figure 2




Figure 3





Figure 4

20130324-070512



Figure 5A



**Figure 5B**





Figure 6A

**Figure 6B**



**This Page is Inserted by IFW Indexing and Scanning  
Operations and is not part of the Official Record**

**BEST AVAILABLE IMAGES**

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:

**BLACK BORDERS**

**IMAGE CUT OFF AT TOP, BOTTOM OR SIDES**

**FADED TEXT OR DRAWING**

**BLURRED OR ILLEGIBLE TEXT OR DRAWING**

**SKEWED/SLANTED IMAGES**

**COLOR OR BLACK AND WHITE PHOTOGRAPHS**

**GRAY SCALE DOCUMENTS**

**LINES OR MARKS ON ORIGINAL DOCUMENT**

**REFERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY**

**OTHER:** \_\_\_\_\_

**IMAGES ARE BEST AVAILABLE COPY.**

**As rescanning these documents will not correct the image problems checked, please do not report these problems to the IFW Image Problem Mailbox.**